OBIOOrchestra BioMed Holdings, Inc.
$5.73+110% 1Y
$5.73
$2.8752 weeks$6.36
OBIO in its own filings
OBIO's filing record carries 3 kinds of hard flag, each is shown beside the share of the whole market carrying the same one, because more than half of all companies carry at least one.
106
Events found in the filings · across 409 filings · the record starts in 2020
- Hard flags
- 3
Hard flags
- Most recent filing
- Oct 1, 2026
Most recent filing · Form 8-K
- Record starts
- Jul 30, 2020
Record starts · the earliest filing Ryufin holds for this name
Details›
- Restatement admitted (non-reliance)historical
- 2022-02-10
- Change in certifying accountanthistorical
- 2023-01-31
- Delisting notice / listing-rule failurehistorical
- 2023-01-24
- SEC comment-letter activity23 occurrences
- 2024-05-22
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Oct 1, 2026On October 1, 2026, the Company announced that, as of September 30, 2026, 330 patients had been randomized in the BACKBEAT Global Pivotal Trial (“BACKBEAT Trial”), exceeding its previously announced target of 316 randomized patients.Regulation FD disclosure · Form 8-K
- Sep 8, 2026Accelerating high - impact technologies to patients through risk - reward sharing partnerships Corporate Overview | September 2026 Nasdaq: OBIO.Regulation FD disclosure · press release
- Feb 13, 2026Cash Bonus Plan On February 12, 2026, the Board of Directors (the “Board”) of Orchestra BioMed Holdings, Inc. (the “Company”), upon the recommendation of the Compensation Committee of the Board (the “Compensation Committee”), approved the 2026 cash bonus plan for all executive officers (the “Plan”), which: · …Director or officer change · Form 8-K
- Jan 12, 2026Orchestra BioMed to Receive Up to $21 Million.Other event · press release
- Nov 13, 2025Quarter 2025 Corporate Update Conference Call.Regulation FD disclosure · press release
- Oct 30, 2025Forward-Looking Statements.Regulation FD disclosure · press release
- Oct 28, 2025Termination and Right of First Refusal Agreement On October 24, 2025 (the “Effective Date”), Orchestra BioMed, Inc. (“Orchestra”), a wholly owned subsidiary of Orchestra BioMed Holdings, Inc. (the “Company”), entered into a termination and right of first refusal agreement (the “Termination and ROFR Agreement”) with …Material agreement entered · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…